



9th March 2017

CHMP Chairman
European Medicines Agency
7 Westferry Circus
Canary Wharf
London
E14 4HB
United Kingdom

**Subject: Withdrawal of Blectifor (caffeine citrate) 10mg/ml Solution for Injection and Oral Solution
EMEA/H/C/004100**

Dear CHMP Chairman,

For the withdrawal of initial marketing authorisation application

I would like to inform you that, at this point of time, Viridian Pharma Limited has taken the decision to withdraw the application for Marketing Authorisation of Blectifor (caffeine citrate) 10mg/ml Solution for Injection and Oral Solution which was intended to be used for the prevention of bronchopulmonary dysplasia in preterm neonates.

The withdrawal is based on the following reason outlined below;

We have been acquired by a French company Ethypharm on 28th February 2017. Ethypharm, would now like us to withdraw the application for Blectifor immediately following this acquisition because currently there is no commercial interest for marketing this drug product.

We reserve the right to make further submissions at a future date in this or other therapeutic indication(s).

I agree for this letter to be published on the EMEA website.

Yours sincerely,

